Historical wst News Stories
West Pharmaceutical Services to Release Q2 2026 Financial Results Amidst Strategic Developments
West Pharmaceutical Services to announce Q2 2026 results on July 23, 2026.
West Pharmaceutical Services Faces Operational Challenges Amid Cyberattack
West Pharmaceutical Services reports operational disruptions due to a recent cyberattack.
West Pharmaceutical Services Recovers from Cyberattack, Maintains Strong Financial Outlook
West Pharmaceutical Services restores operations post-cyberattack, affirms 2026 financial guidance.
WST Q1 Beat Spurs GLP-1 Growth, Dublin Gains! YTD.
West Pharmaceutical (WST) delivered a strong Q1 beat with $844.9M in sales and $2.13 adjusted EPS, raised 2026 guidance, and highlighted GLP‑1 demand, Annex 1 conversions, and the new Dublin contract-services facility as key growth drivers while executing a sizable buyback.
WST Rally: $1B Buyback, Q4 Beats & 2026 Upbeat Now
West Pharmaceutical Services (WST) strengthened its shareholder case this week with a $1 billion open buyback, a maintained quarterly dividend and Q4 results that topped expectations. Management’s 2026 guidance, operational fixes and strategic moves around HVP and GLP‑1 exposure support the stock’s near‑term momentum, while execution risks warrant monitoring.
WST: CEO Exit, Buybacks & Q4 Strength Boost Stock.
West Pharmaceutical Services (WST) saw investor optimism after a managed CEO succession announcement, solid Q4 and FY2025 results, a large share-repurchase authorization and continued sector demand for advanced pharma packaging. Near-term catalysts include the planned divestiture of the SmartDose 3.5 mL business and analyst upgrades that lift price targets well above current levels.
WST: Packaging Demand Sparks Sustained Rally Ahead
West Pharmaceutical (WST) outperformed peers late February with a short-lived rally, buoyed by sector tailwinds in sterile pharmaceutical packaging. No company-specific catalysts emerged last week; investors should watch upcoming earnings, volume trends, and regulatory or supply-chain updates that could move the stock.
WST Stock: GLP-1 Demand Fuels Q4 Beat; Shares Slip
West Pharmaceutical beat Q4 expectations driven by GLP‑1 injectable demand, but the stock showed short-term volatility and remains below its 52‑week peak. Strong financials, improving technicals and high-margin product mix underpin the outlook, while investors watch for sustained price strength.
WST Strategic Pivot: Synchrony S1, SmartDose Exit.
West Pharmaceutical (WST) has accelerated a strategic shift: launching the Synchrony™ S1 prefilled syringe system while agreeing to sell its SmartDose® 3.5 mL on‑body injector business to AbbVie. Recent moves aim to concentrate resources on high‑value injectable solutions even as the stock lags peers.
WST Falls 2.29% on Broad Selloff; Volume Jumps Now
West Pharmaceutical Services (WST) dropped 2.29% on Feb 5, 2026, amid a broader market decline. Trading volume spiked to ~1.2M shares — well above the 50-day average — while no company-specific news surfaced. This article breaks down the move, peer behavior, and what investors should monitor next.